Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TSPO | P30536 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 2/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24343242 | 0.89 | HSD17B2 (0.50) | HSD17B2MEN1KMT2ATSPOALDH1A1 | |
| SCHEMBL29234302 | 0.85 | TSHR (0.57) | HSD17B2MEN1KMT2ATSPOPTGES | |
| SCHEMBL29469525 | 0.85 | TSHR (0.57) | HSD17B2MEN1KMT2ATSPOPTGES | |
| SCHEMBL9416588 | 0.85 | HSD17B2 (0.57) | HSD17B2MEN1KMT2ATSPOSMN1; SMN2 | |
| SCHEMBL30246316 | 0.84 | HSD17B2 (0.56) | HSD17B2MEN1KMT2ATSPOMTNR1A | |
| SCHEMBL7179678 | 0.84 | HSD17B2 (0.56) | HSD17B2MEN1KMT2ATSPOMTNR1A | |
| SCHEMBL30945862 | 0.81 | TSPO (0.54) | HSD17B2MEN1KMT2ATSPOMTNR1A | |
| SCHEMBL30855383 | 0.81 | TSPO (0.54) | HSD17B2MEN1KMT2ATSPOMTNR1A | |
| SCHEMBL30644030 | 0.81 | BCHE (0.64) | HSD17B2TSPOMTNR1AMTNR1BPTGES | |
| SCHEMBL6122371 | 0.81 | BCHE (0.64) | HSD17B2TSPOMTNR1AMTNR1BPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220118086-A1 | INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118086-A1 | INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | ICOS, CD47, CD274 | HSD17B2 3593/4885MEN1 2690/4885KMT2A 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.